Omega Therapeutics, Inc.
OMGA evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Lead Asset:
- otx-2002 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for OMGA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
otx-2002 (Phase 1/Phase 2)
Next Catalyst
—
Tracking 1 pipeline candidate for Omega Therapeutics, Inc..
Run Omega Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Omega Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is Omega Therapeutics, Inc.'s lead drug candidate?
Omega Therapeutics, Inc.'s most advanced tracked candidate is otx-2002 (Phase 1/Phase 2) for Hepatocellular carcinoma (HCC).
Who is the CEO of Omega Therapeutics, Inc.?
Mahesh Karande is the chief executive officer of Omega Therapeutics, Inc. (OMGA).
What therapeutic areas does Omega Therapeutics, Inc. focus on?
Omega Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.